Active Versus Vehicle Home Care During PRX S Treatment for Mild-to-Moderate Facial Acne (PRXS-HOME-RCT)

November 17, 2026 updated by: Medical University of Silesia

Adjunctive Effects of Active Balancing Cream Versus Its Vehicle During Five PRX S Sessions in Adults With Mild-to-Moderate Facial Acne: A Randomized Parallel-Group Clinical and Instrumental Study

This prospective, randomized, parallel-group study aims to evaluate the additional effects of active Balancing Cream compared with its vehicle during a standardized series of five PRX S treatments in adults with mild-to-moderate facial acne.

A total of 50 participants aged 18-60 years with dermatologist-confirmed mild-to-moderate facial acne (Investigator's Global Assessment [IGA] grade 2 or 3) will be enrolled and allocated to two groups of 25 participants each.

Both groups will receive five PRX S treatments at 14-day intervals and use the same Nourishing Cream for Normal and Combination Skin in the morning. In the evening, the experimental group will apply active Balancing Cream containing azelaic acid, salicylic acid, and niacinamide, while the comparator group will use a corresponding cream vehicle without these three ingredients.

The primary outcome is the change from baseline in the total number of facial inflammatory lesions (papules and pustules), assessed two weeks after the fifth PRX S treatment. Secondary assessments include acne severity, non-inflammatory lesion counts, skin biophysical and imaging measurements, and treatment safety.

Clinical and instrumental assessments will be performed at baseline (T0), approximately day 42 (T1), approximately day 70 (T2), and two months after T2 (T3).

The study is designed to assess the additional benefit of active Balancing Cream compared with its vehicle under identical PRX S treatment conditions, rather than the independent efficacy of PRX S.

Study Overview

Detailed Description

This prospective, randomized, two-arm, parallel-group clinical study will investigate whether active Balancing Cream provides additional clinical and instrumental benefits compared with its corresponding vehicle when used as adjunctive home care during a standardized series of five PRX S treatments in adults with mild-to-moderate facial acne.

**Study Design and Participants**

The study will include 50 adults aged 18-60 years with dermatologist-confirmed mild-to-moderate facial acne, defined as Investigator's Global Assessment (IGA) grade 2 or 3 and at least five inflammatory lesions (papules and pustules) on the face.

Following eligibility assessment, written informed consent, and baseline measurements, participants will be randomized in a 1:1 ratio to two parallel treatment groups, with 25 participants planned per group. Randomization is planned using computer-generated permuted blocks of varying sizes, stratified by baseline IGA grade (2 or 3). Allocation concealment and masking procedures will be finalized and approved before enrollment.

**Treatment Groups**

Group A (Experimental): Participants will receive five PRX S treatments and use Nourishing Cream for Normal and Combination Skin in the morning and active Balancing Cream containing azelaic acid, salicylic acid, and niacinamide in the evening.

Group B (Vehicle Comparator): Participants will receive the same five PRX S treatments and use the same Nourishing Cream in the morning and a corresponding Balancing Cream vehicle without azelaic acid, salicylic acid, and niacinamide in the evening.

PRX S will be applied externally to the facial skin on days 0, 14, 28, 42, and 56, according to the manufacturer's instructions and a standardized treatment procedure. Both groups will follow identical cleansing and photoprotection recommendations. Assigned home care will continue from baseline (T0) through the final follow-up visit (T3).

The study interventions differ only in the assigned Balancing Cream formulation. The comparator vehicle is not intended to represent a placebo for the PRX S treatment.

**Assessment Schedule**

Clinical and instrumental assessments will be conducted at four time points:

  • T0: Baseline, before the first PRX S treatment and initiation of assigned home care.
  • T1: Approximately day 42, after three PRX S treatments and before the fourth treatment.
  • T2: Approximately day 70, 14 days after the fifth PRX S treatment.
  • T3: Two calendar months after T2, during continued assigned home care.

**Clinical and Instrumental Assessments**

Clinical evaluations will include counts of inflammatory facial lesions (papules and pustules), non-inflammatory lesions (open and closed comedones), and acne severity according to the IGA scale.

The instrumental assessment panel will include:

  • Antera 3D imaging for prespecified skin pore, texture, and roughness parameters.
  • Standardized facial photography using Fotomedicus.
  • Sebumetry to evaluate skin sebum levels.
  • Corneometry to assess skin hydration.
  • Cutometry to evaluate skin elasticity, including the R2 parameter.
  • Skin ultrasonography to assess dermal thickness and echogenicity.

Measurements will be performed on predefined facial areas under standardized conditions.

**Primary Outcome and Statistical Analysis**

The primary outcome is the individual change in total facial inflammatory lesion count from baseline (T0) to T2, calculated as the number of papules and pustules at T2 minus the corresponding baseline count.

The primary analysis will compare the experimental and vehicle groups using analysis of covariance (ANCOVA), adjusting for baseline inflammatory lesion count and baseline IGA stratum (2 or 3).

A negative adjusted difference between the experimental and comparator groups will favor the active Balancing Cream.

Secondary outcomes will include changes in non-inflammatory lesion counts, percentage reduction in inflammatory lesions, IGA scores and response rates, longitudinal skin biophysical parameters, imaging measurements, and safety outcomes. Secondary analyses will be exploratory.

**Safety Monitoring**

Treatment tolerability, adverse events, adherence to assigned home care, and concomitant acne treatments will be monitored throughout the study.

Participants experiencing clinically significant irritation, allergic reactions, infection, or acne worsening will undergo dermatological assessment. Treatment interruption, discontinuation, or rescue therapy will be implemented when clinically indicated.

The study will evaluate the added effect of the three ingredients present in active Balancing Cream within a common PRX S treatment and home-care regimen. It is not designed to determine the independent efficacy of PRX S compared with no PRX S treatment.

Study Type

Interventional

Enrollment (Estimated)

50

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Mysłowice, Poland
        • AJ Med
        • Contact:
      • Sosnowiec, Poland, 41-208
        • Department of Practical Cosmetology and Skin Diagnostics, Medical University of Silesia
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 60 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Adults aged 18-60 years.
  • Mild-to-moderate facial acne vulgaris, defined as Investigator's Global Assessment (IGA) grade 2 or 3, confirmed by a dermatologist at baseline (T0).
  • Presence of at least five countable inflammatory facial acne lesions (papules and pustules).
  • Written informed consent to participate in the study and undergo study-related documentation.
  • No contraindications to the study interventions, with clinical suitability confirmed by a dermatologist.
  • Ability and willingness to comply with scheduled study visits and assigned home-care procedures.
  • No immediate need for alternative acne treatment that is not provided within the study protocol.

Exclusion Criteria:

  • IGA grade 0, 1, or 4.
  • Severe or nodulocystic acne, or rapidly progressive acne scarring.
  • Pregnancy or breastfeeding.
  • Known hypersensitivity or allergy to any ingredient of the study products.
  • Active skin infections, including herpes simplex, open wounds, erosions, or burns in the treatment area.
  • Active atopic dermatitis, seborrheic dermatitis, or other dermatological conditions that could interfere with study assessments.
  • Malignant or suspicious skin lesions in the treatment area.
  • Clinically relevant diseases or treatments that may increase the risk associated with study interventions or interfere with study outcomes.
  • Use of topical retinoids within 30 days before baseline (T0).
  • Completion of anti-acne antibiotic therapy less than 3 months before baseline (T0).
  • Completion of isotretinoin treatment less than 6 months before baseline (T0).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: PRX S + Active Balancing Cream

Participants in this arm will receive five PRX S treatments applied to the facial skin at 14-day intervals (days 0, 14, 28, 42, and 56). In addition, participants will use Nourishing Cream for Normal and Combination Skin in the morning and active Balancing Cream containing azelaic acid, salicylic acid, and niacinamide in the evening, from baseline (T0) through the final follow-up visit (T3).

PRX S is a professional topical treatment applied to the facial skin after product activation according to the manufacturer's instructions and a standardized procedure. Participants will receive five treatment sessions at 14-day intervals on days 0, 14, 28, 42, and 56. The same PRX S treatment protocol will be used in both study arms.

Active Balancing Cream is a topical facial cream containing azelaic acid, salicylic acid, and niacinamide. Participants assigned to the experimental arm will apply the cream to the facial skin in the evening as part of their home-care regimen, from baseline (T0) through the final follow-up visit (T3). The cream will be used alongside five PRX S treatments and morning application of Nourishing Cream for Normal and Combination Skin.

Nourishing Cream for Normal and Combination Skin is a topical facial moisturizer used as standardized morning home care in both study arms. Participants will apply the cream in the morning from baseline (T0) through the final follow-up visit (T3), alongside their assigned evening Balancing Cream formulation and five PRX S treatments.

Placebo Comparator: PRX S + Balancing Cream Vehicle

Participants in this arm will receive the same five PRX S treatments applied to the facial skin at 14-day intervals (days 0, 14, 28, 42, and 56). Participants will use the same Nourishing Cream for Normal and Combination Skin in the morning and a corresponding Balancing Cream vehicle without azelaic acid, salicylic acid, and niacinamide in the evening, from baseline (T0) through the final follow-up visit (T3). The vehicle serves as a comparator for the active Balancing Cream, not for PRX S treatment.

PRX S is a professional topical treatment applied to the facial skin after product activation according to the manufacturer's instructions and a standardized procedure. Participants will receive five treatment sessions at 14-day intervals on days 0, 14, 28, 42, and 56. The same PRX S treatment protocol will be used in both study arms.

Nourishing Cream for Normal and Combination Skin is a topical facial moisturizer used as standardized morning home care in both study arms. Participants will apply the cream in the morning from baseline (T0) through the final follow-up visit (T3), alongside their assigned evening Balancing Cream formulation and five PRX S treatments.

Balancing Cream Vehicle is a corresponding topical facial cream formulation without azelaic acid, salicylic acid, and niacinamide. Participants assigned to the comparator arm will apply the vehicle to the facial skin in the evening as part of their home-care regimen, from baseline (T0) through the final follow-up visit (T3). The vehicle will be used alongside five PRX S treatments and morning application of Nourishing Cream for Normal and Combination Skin.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change From Baseline in Facial Inflammatory Lesion Count
Time Frame: Baseline (Day 0) and 2 weeks after the fifth PRX S treatment (approximately Day 70).

Absolute individual change in the total number of facial inflammatory lesions (papules and pustules), calculated as the lesion count at T2 minus the baseline count at T0. The unit of measurement is number of lesions. Negative values indicate improvement. The primary comparison between active Balancing Cream and vehicle groups will use ANCOVA adjusted for baseline inflammatory lesion count and baseline IGA stratum (2 or 3).

Baseline (Day 0) and 2 weeks after the fifth PRX S treatment (approximately Day 70).

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change From Baseline in Facial Non-Inflammatory Lesion Count
Time Frame: Baseline (Day 0), approximately Day 42, approximately Day 70, and 2 calendar months after the Day 70 assessment.

Change from baseline in the total number of facial non-inflammatory acne lesions, including open and closed comedones. The unit of measurement is number of lesions.

Baseline (Day 0), approximately Day 42, approximately Day 70, and 2 calendar months after the Day 70 assessment.
Percentage Reduction in Facial Inflammatory Lesion Count
Time Frame: Baseline (Day 0), approximately Day 42, approximately Day 70, and 2 calendar months after the Day 70 assessment.

Percentage reduction in the total number of facial papules and pustules relative to baseline, calculated as 100 × (baseline lesion count - follow-up lesion count) / baseline lesion count.

Baseline (Day 0), approximately Day 42, approximately Day 70, and 2 calendar months after the Day 70 assessment.
Change From Baseline in Facial Inflammatory Lesion Count at Day 42 and Final Follow-Up
Time Frame: Baseline (Day 0), approximately Day 42, and 2 calendar months after the Day 70 assessment.

Absolute change in the total number of facial inflammatory lesions (papules and pustules) from baseline to T1 and T3. The unit of measurement is number of lesions. Negative values indicate improvement.

Baseline (Day 0), approximately Day 42, and 2 calendar months after the Day 70 assessment.
Investigator's Global Assessment (IGA) of Acne Severity
Time Frame: Baseline (Day 0), approximately Day 42, approximately Day 70, and 2 calendar months after the Day 70 assessment.

Facial acne severity assessed using the Investigator's Global Assessment (IGA), an ordinal scale from 0 to 4. The distribution of IGA grades and changes over time will be evaluated.

Baseline (Day 0), approximately Day 42, approximately Day 70, and 2 calendar months after the Day 70 assessment.
Proportion of Participants Achieving IGA Grade 0 or 1
Time Frame: Baseline (Day 0), approximately Day 42, approximately Day 70, and 2 calendar months after the Day 70 assessment.

Percentage of participants achieving an Investigator's Global Assessment (IGA) grade of 0 or 1 at each follow-up assessment.

Baseline (Day 0), approximately Day 42, approximately Day 70, and 2 calendar months after the Day 70 assessment.
Proportion of Participants Achieving IGA Treatment Success
Time Frame: Baseline (Day 0), approximately Day 42, approximately Day 70, and 2 calendar months after the Day 70 assessment.

Percentage of participants achieving an IGA grade of 0 or 1 together with an improvement of at least 2 grades from baseline. Results will be described according to baseline IGA grade (2 or 3).

Baseline (Day 0), approximately Day 42, approximately Day 70, and 2 calendar months after the Day 70 assessment.
Change From Baseline in Facial Skin Sebum Level
Time Frame: Baseline (Day 0), approximately Day 42, approximately Day 70, and 2 calendar months after the Day 70 assessment.

Skin sebum level measured by sebumetry in standardized facial areas. Results will be expressed in micrograms per square centimeter (µg/cm²).

Baseline (Day 0), approximately Day 42, approximately Day 70, and 2 calendar months after the Day 70 assessment.
Change From Baseline in Skin Hydration
Time Frame: Baseline (Day 0), approximately Day 42, approximately Day 70, and 2 calendar months after the Day 70 assessment.

Skin hydration assessed by corneometry in standardized facial areas. Results will be expressed in arbitrary units.

Baseline (Day 0), approximately Day 42, approximately Day 70, and 2 calendar months after the Day 70 assessment.
Change From Baseline in Skin Elasticity (Cutometer R2)
Time Frame: Baseline (Day 0), approximately Day 42, approximately Day 70, and 2 calendar months after the Day 70 assessment.

Skin elasticity assessed using the Cutometer R2 parameter in standardized facial areas. R2 is a dimensionless measurement.

Baseline (Day 0), approximately Day 42, approximately Day 70, and 2 calendar months after the Day 70 assessment.
Change From Baseline in Dermal Thickness
Time Frame: Baseline (Day 0), approximately Day 42, approximately Day 70, and 2 calendar months after the Day 70 assessment.

Dermal thickness assessed by skin ultrasonography in standardized facial areas. Results will be expressed in millimeters (mm).

Baseline (Day 0), approximately Day 42, approximately Day 70, and 2 calendar months after the Day 70 assessment.
Change From Baseline in Dermal Echogenicity
Time Frame: Baseline (Day 0), approximately Day 42, approximately Day 70, and 2 calendar months after the Day 70 assessment.

Dermal echogenicity assessed by skin ultrasonography under standardized measurement settings. Results will be expressed in arbitrary units.

Baseline (Day 0), approximately Day 42, approximately Day 70, and 2 calendar months after the Day 70 assessment.
Incidence of Adverse Events During Treatment and Follow-Up
Time Frame: From the first study intervention (Day 0) through the final follow-up visit, approximately 2 calendar months after Day 70.

Number and percentage of participants experiencing adverse events, including local skin reactions and acne worsening. Adverse event severity, seriousness, relationship to study interventions, treatment interruptions, discontinuations, and rescue therapy will be recorded.

From the first study intervention (Day 0) through the final follow-up visit, approximately 2 calendar months after Day 70.
Change From Baseline in Facial Skin Pore Parameters Assessed by Antera 3D
Time Frame: Baseline (Day 0), approximately Day 42, approximately Day 70, and 2 calendar months after the Day 70 assessment.

Changes in facial skin pore parameters assessed using Antera 3D imaging in standardized facial areas at baseline and follow-up visits. The assessment will use prespecified Antera 3D pore-related outputs.

Baseline (Day 0), approximately Day 42, approximately Day 70, and 2 calendar months after the Day 70 assessment.
Change From Baseline in Facial Skin Texture Assessed by Antera 3D
Time Frame: Baseline (Day 0), approximately Day 42, approximately Day 70, and 2 calendar months after the Day 70 assessment.

Changes in facial skin texture assessed by Antera 3D imaging in standardized facial areas. Measurements will be performed at baseline and scheduled follow-up visits using prespecified skin texture parameters.

Baseline (Day 0), approximately Day 42, approximately Day 70, and 2 calendar months after the Day 70 assessment.
Change From Baseline in Facial Skin Roughness Assessed by Antera 3D
Time Frame: Baseline (Day 0), approximately Day 42, approximately Day 70, and 2 calendar months after the Day 70 assessment.

Changes in facial skin roughness assessed using Antera 3D imaging in standardized facial areas at baseline and follow-up visits. The assessment will use prespecified Antera 3D roughness parameters.

Baseline (Day 0), approximately Day 42, approximately Day 70, and 2 calendar months after the Day 70 assessment.
Standardized Facial Photography Using Fotomedicus
Time Frame: Baseline (Day 0), approximately Day 42, approximately Day 70, and 2 calendar months after the Day 70 assessment.

Standardized facial photographs will be obtained using the Fotomedicus system at baseline and scheduled follow-up visits to document facial skin appearance and visible acne lesions over time.

Baseline (Day 0), approximately Day 42, approximately Day 70, and 2 calendar months after the Day 70 assessment.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

Investigators

  • Principal Investigator: Anna Deda, PhD, Medical University of Silesia in Katowice

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

December 1, 2026

Primary Completion (Estimated)

March 30, 2027

Study Completion (Estimated)

May 31, 2027

Study Registration Dates

First Submitted

November 10, 2026

First Submitted That Met QC Criteria

November 17, 2026

First Posted (Actual)

November 18, 2026

Study Record Updates

Last Update Posted (Actual)

November 18, 2026

Last Update Submitted That Met QC Criteria

November 17, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

De-identified individual participant data and the accompanying data dictionary will be made available to researchers upon reasonable request, subject to participant consent and the applicable data-sharing policies of the Medical University of Silesia in Katowice.

IPD Sharing Time Frame

Following publication of the study results, with no predetermined end date for considering data access requests.

IPD Sharing Access Criteria

Access to de-identified individual participant data and the data dictionary will be considered upon reasonable request, subject to participant consent and the applicable policies of the Medical University of Silesia in Katowice.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ICF
  • CSR

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe